In a prospective, randomized, blind study, we assessed the effectiveness of droperidol 20 ug kg" 1 i.v., given at induction of anaesthesia, in preventing postoperative vomiting in paediatric day-case patients. We studied 270 children, aged 1-15 yr, undergoing body surface surgery. There was a significant reduction in the incidence of vomiting in the recovery room (1.4% vs 9.2%, P < 0.005) and in the day ward (9.4% vs 18.3%, P < 0.05) in patients receiving droperidol. There was no significant difference on the journey home (9.5% vs 17.83%, ns) or at home (16.7% vs 10.3%, ns). There was also a reduction in the severity of vomiting in the droperidol group. There were no adverse side effects. (Br. J. Anaesth. 1995; 74: 509-511) 
Postoperative nausea and vomiting are common in paediatric day care [1, 2] . They may delay discharge home, resumption of oral intake and cause distress to child and parents. Various studies have reported incidences of vomiting of 41-58 % for body surface surgery and 56-76 % after strabismus correction [1, 3, 4] .
The efficacy of low-dose droperidol as antiemetic prophylaxis has been established in several studies, particularly in gynaecology, paediatric inpatient and strabismus surgery [4] [5] [6] [7] . Pandit and colleagues established that droperidol 10-20 ug kg" 1 was effective in reducing the incidence of postoperative vomiting after laparoscopy in adult females without the adverse side effects associated with higher doses, for example prolonged recovery, dizziness or extrapyramidal signs [6] .
Therefore, we have determined the efficacy and side effects of 20 ug kg" 1 in paediatric day-case anaesthesia.
Patients and methods
After obtaining Hospital Ethics Committee approval and written informed parental consent, we studied 270 paediatric day-case surgical patients, aged 1-15 yr, undergoing elective body surface surgery. Details of medical history, history of vomiting with previous anaesthesia or motion sickness, time of last oral intake and drug history were recorded and also the distance required to travel home. Patients were allocated randomly by a computer generated randomization sequence to one of two groups; treatment (n = 144) and control (w = 126). No premedication was given other than the application of EMLA cream to the dorsum of one or both hands.
Anaesthesia was induced with either thiopentone 5 mg kg" 1 or by inhalation of increasing concentrations of halothane and 66 % nitrous oxide in oxygen if venous cannulation was unsuccessful. Anaesthesia was maintained with nitrous oxide and 1-2 % halothane in oxygen with the patient breathing spontaneously via a T-piece (weight < 20 kg) or Bain circuit (weight > 20 kg). Local anaesthetic techniques were used widely as appropriate; either regional (sacral extradural block), peripheral nerve block or local infiltration by the surgeon. Opioid drugs were not used. Parents were advised to administer paracetamol (24 mg ml" 1 ) at a dose of 10 mg kg" 1 as required after discharge. Those in the treatment group received droperidol 20 ug kg" 1 i.v. before surgery.
Postoperative vomiting was assessed by the nursing staff, who were blinded, in recovery and in the day ward. In the recovery area, the occurrence and number of episodes of vomiting or retching and the time of spontaneous eye opening were recorded. For the purposes of this study, vomiting or retching was recorded as a vomiting episode. After return to the day ward, the occurrence and number of vomiting episodes, and the time to discharge from the day unit were recorded. Further information, including emesis on the way home or at home, and time to intake of solids was ascertained from a questionnaire completed by the parents. A stamped addressed envelope was provided, followed by written or telephone reminders in the event of failure to return the questionnaire. The parents were blinded also to the patient's group. Patients with severe vomiting were to receive metoclopramide and be admitted if prolonged.
In sample size and power calculations, we esti- •Address for correspondence: Department of Anaesthesia, Royal Naval Hospital, Stonehouse, Plymouth PL1 3JY.
vomiting. Using values for a of 0.05 and p of 0.2, we determined a sample size requirement of 148 patients in each group.
The treated and control groups were compared on an intention-to-treat basis, that is eight design violators were included in the analysis. At each assessment time (recovery, day unit, journey home, at home) the difference in rate of vomiting between the two groups was determined and 95 % confidence intervals calculated for these differences. The significance of any difference was assessed using chisquare tests, or Fisher's exact test with calculated two-tailed probability if numbers were small. Time to spontaneous eye opening, time to discharge, time to solid intake and number of vomiting events were compared using two-sample t tests and MannWhitney U tests, but only the latter are presented because data were skewed. All tests were judged significant at the 5 % level.
Results
A total of 144 patients were allocated randomly to receive droperidol and 126 to the control group. Eight patients were withdrawn from the study for the following reasons: opioid analgesia (« = 4), nonstandard anaesthetic (w = 1), operation cancelled (« = 1), endoscopic procedure (n = 1) and admission for surgical reasons («= 2). Three were in the droperidol group and five in the control group. Three patients were admitted because of severe vomiting (more than four vomiting events in the day ward); all three had received droperidol. Another patient in the droperidol group, having been taken home, was admitted with vomiting to another hospital later that day. Fifteen patients (10.41 %) in the droperidol group and 17 (13.49 %) in the control group failed to return the questionnaires despite follow-up letters and telephone calls. Patient characteristics were similar in both groups (table 1). There was no significant difference in the time to spontaneous eye opening, discharge home or oral intake of solids (table 2) between the two groups.
Patients in the droperidol group had a statistically significantly lower incidence of vomiting in recovery and in the day ward (table 3) . However, for the journey home, the difference did not reach significance. The droperidol group had a higher incidence of vomiting at home but this was not statistically significant. Of the patients with no previous history of motion sickness, the overall incidence of vomiting on the journey home was 12.3 % compared with 20.7 % in those with a positive history (ns, two-tailed Fisher's exact test). Overall, the difference between the two groups in terms of numbers of episodes of vomiting was not significant (25.2% vs 34.6%, P = 0.074). The mean number of vomiting episodes per patient in the control group was 1.2 compared with 0.7 in the droperidol group. There was a significant reduction in the number of vomiting events (and the number of patients who vomited) in the droperidol group in recovery (P = 0.05). The frequency distribution of the vomiting episodes is shown in table 4. There was a significant difference in the frequency distribution, suggesting a reduction in the severity of vomiting in the treated group, both in recovery and the day-case unit. There was a large and significant difference in the vomiting rate in hospital and a small insignificant difference after discharge (table 5) .
Discussion
Droperidol is a neuroleptic butyrophenone derivative that exerts its antiemetic effect via central dopaminergic block. There are many difficulties in comparing studies of postoperative antiemetic drugs because of the multifactorial aetiology of postoperative vomiting and differences in study design. This subject has been discussed recently and solutions have been suggested by Kortilla [8] . It is not surprising that the results of existing studies on the efficacy of droperidol as a postoperative antiemetic drug are conflicting. High doses (50-70 ug kg" 1 ) are associated with drowsiness, delayed discharge and occasionally extrapyramidal side effects. Restlessness and anxiety may occur also and be delayed in onset. Lower doses have thus been used in an attempt to retain the antiemetic properties while reducing the adverse effects. Rita, Goodarzi and Seleny showed that droperidol 5 ug kg" 1 was effective in paediatric inpatient orthopaedic surgery but only in the age group 11-15 yr [7] .
Strabismus surgery is a particularly potent emetic stimulus in children and several studies have produced conflicting results. Lerman, Eustis and Smith investigated droperidol 75 ug kg" 1 and the incidence of postoperative vomiting was reduced significantly in day-case patients with no adverse effects [4] . On the other hand, Hardy and colleagues failed to show any reduction in vomiting in children aged 1-6 yr undergoing strabismus surgery after droperidol 50 ugkg" 1 . Lin, Furst and Rodarte investigated the effect of droperidol 25 ug kg" 1 and showed a significant reduction in emesis compared with controls (33 % vs 88 %). There were no adverse side effects [9] .
A study of the effects of low-dose droperidol in patients undergoing day-case paediatric surgery has not, to our knowledge, been undertaken previously. Our study has shown a statistically significant reduction in postoperative vomiting in patients receiving droperidol 20 ug kg" 1 compared with controls in recovery and before discharge from hospital. This represents a six-fold reduction in recovery and a two-fold reduction in the day unit. Although our study failed to show any reduction in the time to discharge in the droperidol group, we believe that a valuable reduction in morbidity was achieved. However, the droperidol group had an insignificantly greater incidence of vomiting at home.
Because of concern over side effects, many anaesthetists seem to tolerate a higher incidence of postoperative vomiting in their paediatric patients than would be acceptable in their more vociferous adult patients. Many parents seem to expect their children to vomit after operation and, in this study, some refused consent because of a fear of their child receiving an "extra drug". Others refused consent because they considered that a 50% chance of not receiving an antiemetic was unacceptable.
In conclusion, droperidol 20 jig kg" 1 at induction was useful in reducing the incidence of nausea and vomiting in the immediate postoperative period in this group of patients and was apparently free of adverse effects. In those patients that did vomit, there was a non-significant trend towards reduction in severity. This benefit was not prolonged into the later recovery period after discharge from hospital.
